SCHEMBL21247299

SCHEMBL21247299

CC1(C)CCc2sc(NC(=O)c3ccc(N4CCC(O)CC4)cc3)c(C(=O)O)c21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 4/20 0.46
▸ NOD1 Q9Y239 4/20 0.46
▸ CNR1 P21554 2/20 0.44
▸ CNR2 P34972 2/20 0.44
▸ TNIK Q9UKE5 1/20 0.42
▸ MEN1 O00255 7/20 0.41
▸ KMT2A Q03164 7/20 0.41
▸ MAPT P10636 5/20 0.41
▸ GRIN2C Q14957 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ MITF O75030 1/20 0.41
▸ KLF5 Q13887 1/20 0.41
▸ WDR91 A4D1P6 1/20 0.41
▸ GLO1 Q04760 1/20 0.40
▸ RAB9A P51151 4/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21247146 0.88 LMNA (0.47) TNFNOD1MEN1KMT2AMAPT
SCHEMBL21247342 0.84 GLO1 (0.44) TNFNOD1CNR1CNR2MEN1
SCHEMBL21253132 0.81 RAB9A (0.58) NOD1CNR1CNR2MEN1KMT2A
SCHEMBL21247283 0.80 TNF (0.61) TNFNOD1CNR1CNR2MEN1
SCHEMBL22680794 0.80 TNF (0.46) TNFNOD1TNIKMEN1KMT2A
SCHEMBL21247149 0.78 CNR1 (0.43) TNFNOD1CNR1CNR2MEN1
SCHEMBL21247170 0.77 PTPN1 (0.54) TNFNOD1TNIKMEN1KMT2A
SCHEMBL21247261 0.76 GLO1 (0.50) TNFNOD1CNR1CNR2MEN1
SCHEMBL21261089 0.75 GLO1 (0.49) TNFNOD1CNR1CNR2MEN1
SCHEMBL21247405 0.75 RAB9A (0.62) TNFNOD1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11492347-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2022-11-08 — — US disclosed
EP-3749659-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 — — EP disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH TNF 1354/4885NOD1 410/4885CNR1 4561/4885
US-11492347-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH TNF 1354/4885NOD1 410/4885CNR1 4561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback